Number of the records: 1  

Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents

  1. 1.
    0421911 - ÚOCHB 2014 RIV US eng J - Journal Article
    Keough, D. T. - Hocková, Dana - Rejman, Dominik - Špaček, Petr - Vrbková, Silvie - Krečmerová, Marcela - Eng, W. S. - Jans, H. - West, N. P. - Naesens, L. M. J. - de Jersey, J. - Guddat, L. W.
    Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents.
    Journal of Medicinal Chemistry. Roč. 56, č. 17 (2013), s. 6967-6984. ISSN 0022-2623. E-ISSN 1520-4804
    R&D Projects: GA ČR GAP207/11/0108
    Institutional support: RVO:61388963
    Keywords : nucleoside phosphonates * antibacterial agents * hypoxanthine-guanine phosphoribosyltransferase * state analog inhibitor * antimalarial chemotherapy
    Subject RIV: CC - Organic Chemistry
    Impact factor: 5.480, year: 2013

    Escherichia coli (Ec) cells possess two purine salvage enzymes: xanthine-guanine phosphoribosyltransferase (XGPRT) and hypoxanthine phosphoribosyltransferase (HPRT). EcXGPRT shares a common structural feature with other members of this family, a flexible loop that closes over the active site during catalysis. The replacement of six of these amino acids by alanine has no effect on the Km for the two substrates. However, the Ki for the nucleoside monophosphate increases by 27-fold, and the kcat is reduced by 200-fold. Nucleoside phosphonates (NP) are good inhibitors of EcXGPRT and EcHPRT, with Ki values as low as 10 nM. In the absence of the flexible loop, these values increase by 5- to 30-fold, indicating the importance of the loop for high-affinity inhibition. Crystal structures of two NPs in complex with EcXGPRT explain the tight binding. Prodrugs of NPs with low Ki values for EcXGPRT or EcHPRT exhibit IC50 values between 5 and 23 muM against Mycobacterium tuberculosis in cell-based assays, suggesting that these compounds are therapeutic leads against pathogenic bacteria.
    Permanent Link: http://hdl.handle.net/11104/0228188

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.